solute carrier family 22 member 15Genealiases: FLIPT1 · PRO34686
Q-omics provides the consensus-scored SLC22A15 profile across patient tissues and cancer cell-line models. SLC22A15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SLC22A15 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SLC22A15 RNA expression shows 18,805 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where SLC22A15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A15 survival associations across molecular data types. SLC22A15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A15 RNA expression–survival associations across cancer types. High SLC22A15 expression shows unfavorable associations in UCEC, LIHC, STAD, KICH, HNSC and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SLC22A15 RNA expression.
This table summarizes SLC22A15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC22A15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A15 shows lower tumor expression in KIRC and LUAD and higher tumor expression in BLCA, COAD, BRCA and LIHC. The KIRC box plot shows higher SLC22A15 RNA expression in normal versus tumor tissue (log2 FC = −1.269, t-test p < 0.001).
This table shows molecular features associated with SLC22A15 in patient tissues and cancer cell lines. In patient samples, SLC22A15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
